Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.

about

Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.

Item

http://www.wikidata.org/entity/Q54113454

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Association of Dasatinib With ...... Tumors Resistant to Imatinib.

@en

Association of Dasatinib With ...... Tumors Resistant to Imatinib.

@nl

type

Item

label

Association of Dasatinib With ...... Tumors Resistant to Imatinib.

@en

Association of Dasatinib With ...... Tumors Resistant to Imatinib.

@nl

prefLabel

Association of Dasatinib With ...... Tumors Resistant to Imatinib.

@en

Association of Dasatinib With ...... Tumors Resistant to Imatinib.

@nl

P1476

Association of Dasatinib With ...... Tumors Resistant to Imatinib.

@en

P2093

Arthur P Staddon

http://www.w3.org/2001/XMLSchema#string

Brian Samuels

http://www.w3.org/2001/XMLSchema#string

Charles A Forscher

http://www.w3.org/2001/XMLSchema#string

Dafydd G Thomas

http://www.w3.org/2001/XMLSchema#string

Daniel A Rushing

http://www.w3.org/2001/XMLSchema#string

David M Loeb

http://www.w3.org/2001/XMLSchema#string

Denise K Reinke

http://www.w3.org/2001/XMLSchema#string

Dennis A Priebat

http://www.w3.org/2001/XMLSchema#string

Edwin Choy

http://www.w3.org/2001/XMLSchema#string

Gina D'Amato

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor.

Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.

P31

scholarly article

P356

10.1001/JAMAONCOL.2018.0601

http://www.w3.org/2001/XMLSchema#string

P50

Margaret von Mehren

P577

2018-04-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29710216

http://www.w3.org/2001/XMLSchema#string

P932

6145709

http://www.w3.org/2001/XMLSchema#string